Drugs / 68Ga-P16-093
last change Jun 2026 re-read 2 minutes ago

68Ga-P16-093

also known as [68 Ga]Ga-P16-093

Diagnostic / imaging agent

Developed for
prostate cancer
Investigated by
Peking Union Medical College Hospital · First Affiliated Hospital of Fujian Medical University

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT06049368 Oct → Dec 2023 Sjogren syndrome Peking Union Medical College Hospital Unknown No outcome recorded
Phase 1/2 NCT05569434 Nov 2021 → Dec 2023 glioma Peking Union Medical College Hospital Unknown No outcome recorded
Phase 21 trial
Phase 2 NCT07209865 Oct 2024 → Dec 2025 prostate adenocarcinoma First Affiliated Hospital of Fujian Medical University Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04796467 Oct 2020 → Aug 2021 prostate cancer Peking Union Medical College Hospital Unknown No outcome recorded
Phase not applicable2 trials
NCT05324332 Apr 2022 → Jan 2025 overdue prostate cancer Peking Union Medical College Hospital Recruiting No outcome recorded
NCT05432947 Apr → Sep 2022 clear cell renal carcinoma Peking Union Medical College Hospital Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as 68 Ga-P16-093 “PURPOSE: We aimed to compare the diagnostic performance of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients.” PMID 36727866 Jan 2023
6

NCT04796467

NCT07209865

NCT05324332

NCT05432947

NCT05569434

NCT06049368

Known as [68 Ga]Ga-P16-093 “Head-to-head comparison of [(68) Ga]Ga-P16-093 and [(68) Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients.” PMID 34557930 Sep 2021
1

“The newly developed PSMA probe, [68Ga]Ga-P16-093, with low urinary excretion, has shown superior diagnostic efficacy compared to conventional PSMA probes.” PMID 41366119 Dec 2025

Modality Diagnostic / imaging agent “Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.” NCT04796467
Route Intravenous Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093.” NCT04796467